Read the full Entrevestor article here
Two Halifax-area medtech companies – Spring Loaded Technology and Densitas – have received a slice of an $11 million equity funding exercise anchored by the Montreal-based health technology organization Medteq.
Medteq, which nurtures Canadian health-technology innovators, issued a statement saying that its $14 million investment fund made its first investments, backing eight companies based in Montreal and Halifax. MEDTEQ invested alongside co-investors including: Anges-Quebec, Anges-Quebec Capital, Innovacorp, Real Ventures and others.
The target companies included Spring Loaded, which makes advanced knee braces, and Densitas, which assesses the density of breast tissue during mammograms. Innovacorp, the Nova Scotia government’s early-stage venture capital agency, was already an existing investor in both companies.
Halifax-based breast imaging analytics company Densitas has announced a collaboration with TeleMammography Specialists of Decatur, Georgia, that will improve the quality of breast screening offered to more than 60,000 women annually.
TeleMammography Specialists is an international teleradiology services provider and will be the first U.S. beta user for the new densitasquality solution, the company said in a statement. The product will improve the communications and information sharing needed to meet FDA guidelines.
TeleMammography Specialists also plan to implement the recently released densitasdensity automated breast density assessment software.
“Our goal is to provide tools that reduce the documentation, process and communication burdens of meeting EQUIP (FDA) guidelines and enables sustainable delivery of quality assurance across the mammography enterprise,” Mohamed Abdolell, CEO of Densitas, said in the statement.
See full article here
PRNewswire/ – Densitas, Inc., a breast imaging analytics innovator based in Halifax, Nova Scotia, today announced the signing of a new Alliance Partner Agreement with Blackford. This agreement gives Blackford the right to promote, market, sell, distribute, and license densitasdensity™ directly via integration with the Blackford Platform™. Work will now commence to integrate densitasdensity™ with the Blackford Platform.
“The platform approach will help us bring new products to market more quickly, support our scaling activities, and simplify integration for our customers” says Mohamed Abdolell, CEO of Densitas. “We expect the Blackford Platform to reduce our time to market and shorten our sales cycle as we will be incorporated as an extension of the Blackford Platform infrastructure.”
The densitasdensity™ software provides an automated mechanism for quantifying and recording percent breast tissue density, and making it readily available to the radiologist. Beyond speeding and simplifying the process of quantifying breast density, densitasdensity™ standardizes the density measurement which enables uniform application of risk-based stratification of screen eligible women aimed at ensuring those who need more aggressive follow-up receive it, while those who do not need aggressive follow-up do not receive unnecessary imaging. Densitas software is unique in that it assesses breast density using the routinely archived processed DICOM images that radiologists normally review, and therefore supports prospective and retrospective breast density measurement for clinical care and for research.
Blackford CEO, Ben Panter said this of the alliance:
“We are delighted to add densitasdensity™ to the curated marketplace of applications available through Blackford Platform. We look forward to working with Densitas to provide our customers and channel partners multiple imaging applications that can be easily deployed and maintained.”
densitasdensity™ will be demonstrated at the upcoming Radiological Society of North America (RSNA) 2018 annual meeting in Chicago. Densitas personnel will be available to discuss the benefits and capabilities of density in Booth #3274 – South Hall at RSNA and in the machine learning pavilion, Kiosk #7367W – North Hall.
To learn more about Blackford Platform applications including densitasdensity™, book a demo at RSNA or visit Blackford at Booth #7364.
Densitas’ vision is to move the needle in breast cancer screening through tailored patient management for sustainable healthcare service delivery and improved outcomes. Densitas develops advanced breast imaging analytics technologies powered by machine learning with the goal to deliver on-demand actionable insights that improve the quality of breast health management. Our products tackle the key challenges facing women’s imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines, and delivery of appropriate care at sustainable costs. Learn more at www.densitas.health and in our virtual press kit.
Blackford provide a single platform to quickly access and manage a curated marketplace of regulatory approved medical image analysis applications and AI algorithms that add clinical value. Easily integrated into existing workflows, the platform provides actionable information that allows healthcare providers to use imaging information smartly and reduce the cost of care, while improving diagnostic confidence and patient outcomes. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors, one of the UK’s leading business angel syndicates. For more information, visit www.blackfordanalysis.com
Media Contact Densitas:
Media Contact Blackford:
+44 131 6688 411]]>